Should I Buy APRE? APRE 2026 Analysis

Should You Buy Aprea Therapeutics Inc (APRE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.690

1 Day change

10.57%

52 Week Range

4.100

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: current setup is dominated by dilution/financing overhang and a clearly bearish technical trend.
Intellectia signals are absent (no AI Stock Picker and no SwingMax), so there is no high-conviction timing edge for an impatient entry.
Best stance today: hold/avoid new entries until price stabilizes above key levels (pivot ~0.937) or a clear catalyst-driven reversal appears.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend is bearish: SMA_200 > SMA_20 > SMA_5 indicates persistent downtrend across long/medium/short timeframes.
Momentum weakening: MACD histogram is negative (-0.0105) and expanding lower, signaling downside momentum is still building.
RSI_6 at ~36 is weak (near oversold territory but not a strong reversal signal on its own).
Key levels: Support S1 ~0.577 (then S2 ~0.355); resistance/pivot ~0.937, then R1 ~1.297.
Pattern-based expectation provided: ~70% chance of further drift lower (next day -1%, next week -2.33%, next month -1.53%), consistent with the downtrend.

Positive Catalysts

- Insider activity: insiders are buying; buying amount increased ~147% over the last month (a supportive signal vs. current price weakness).
- Clinical/data angle: H.C. Wainwright cites encouraging early proof-of-concept signals for APR-1051 (ongoing Phase 1), which can create sharp upside if follow-up data is strong.
- If the market re-prices back toward financing terms (offering priced at $0.89 with warrants), there could be a technical mean-reversion bounce—though not a confirmed trend change.

Neutral/Negative Catalysts

- Dilution/financing overhang: company announced a securities purchase agreement to sell ~6.29M shares; this is directly negative for near-term price action.
- Warrant structure adds pressure: warrants exercisable at $0.765 (two-year term) can cap rallies and increase effective future share supply.
- Immediate market reaction was negative (stock dropped ~7.83% on the offering news), reinforcing bearish sentiment.
- No strong institutional/hedge fund momentum: hedge funds described as neutral with no significant trend over the last quarter.
- Politicians/influential figures: no reported recent congress trading data available (no external confirmation signal).

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue collapsed: 1,848, down ~99.48% YoY (company remains effectively pre-commercial).
Losses persist: net income -2.97M (down ~21.44% YoY), EPS -0.47 (down ~26.56% YoY), indicating ongoing cash burn typical of early-stage biotech.
Overall: fundamentals depend on pipeline progress/financing rather than operating revenue growth; the new offering underscores continued capital needs.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Rating trend: still a Buy from H.C. Wainwright, but price targets have been cut meaningfully (20 → 5 on 2025-12-18; 5 → 4 on 2026-01-29), largely due to dilution and pipeline focus changes.
Wall Street “pros” view (pros): optimism around APR-1051 early signals and upcoming trial updates.
Wall Street “cons” view (cons): repeated target cuts, dilution risk, and reliance on early-stage data for valuation.

2 Analyst Rating

Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.624

Low

Averages

High

Current: 0.624

Low

Averages

High

H.C. Wainwright

Joseph Pantginis

Buy

downgrade

$5 -> $4

AI Analysis

2026-01-29

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$5 -> $4

AI Analysis

2026-01-29

downgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Aprea Therapeutics to $4 from $5 and keeps a Buy rating on the shares. The firm is "encouraged by the positive," early proof-of-concept data from the ACESOT-1051 study. Aprea reported "promising" preliminary signals from an endometrial cancer patient, the analyst tells investors in a research note. H.C. Wainwright cites dilution for the target cut.

H.C. Wainwright

Buy

downgrade

$20 -> $5

2025-12-18

Reason

H.C. Wainwright

Price Target

$20 -> $5

2025-12-18

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Aprea Therapeutics to $5 from $20 and keeps a Buy rating on the shares after Aprea provided an update on its pipeline progress and corporate outlook for 2026. The company will be shifting focus from its monotherapy study of ATRN-119 to focus on potential combination strategies, notes the analyst, who is adjusting focus to APR-1051, which now provides 100% of the valuation contribution to the firm's model. APR-1051 is currently being evaluated in the ongoing Phase 1 ACESOT-1051 dose-escalation trial and near term catalysts include updated safety and efficacy data due in Q1 and completion of dose escalation expected in 2026, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APRE

Unlock Now

APRE Should I Buy

APRE Should I Buy

Should You Buy Aprea Therapeutics Inc (APRE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch